Oral trovafloxacin compared with amoxicillin (plus optional erythromycin) for the treatment of mild to moderate community-acquired pneumonia

Drugs

Volumn 58, Issue SUPPL. 2, 1999, Pages 320-322

  Daniel, R ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ERYTHROMYCIN; TROVAFLOXACIN;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STREPTOCOCCUS PNEUMONIAE;

HAEMOPHILUS INFLUENZAE; STREPTOCOCCUS PNEUMONIAE;

EID: 0032725445     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958002-00108     Document Type: Conference Paper

References (9)

1. 1. CB Kronenberger RE Hoffman DC Lezotte 1996 Invasive penicillin-resistant pneumococcal infections: a prevalence and historical cohort study Emerg Infect Dis 2 121 4 8903212 10.3201/eid0202.960207 1:STN:280:DyaK2s%2FmsVSrug%3D%3D Kronenberger CB, Hoffman RE, Lezotte DC, et al. Invasive penicillin-resistant pneumococcal infections: a prevalence and historical cohort study. Emerg Infect Dis 1996; 2: 121–4
2. 2. P Geslin A Buu-Hoi A Fremaux 1992 Antimicrobial resistance in Streptococcus pneumoniae: an epidemiological survey in France, 1970–1990 Clin Infect Dis 15 95 8 1617078 10.1093/clinids/15.1.95 1:STN:280:DyaK38zhsValsg%3D%3D Geslin P, Buu-Hoi A, Fremaux A, et al. Antimicrobial resistance in Streptococcus pneumoniae: an epidemiological survey in France, 1970–1990. Clin Infect Dis 1992; 15: 95–8
3. 3. D Pontani H Washton S Bouchillon 1998 Susceptibility patterns of respiratory tract isolates from Europe to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin Eur J Clin Microbiol Infect Dis Pontani D, Washton H, Bouchillon S, et al. Susceptibility patterns of respiratory tract isolates from Europe to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. Eur J Clin Microbiol Infect Dis 1998; 17:413-9
4. 4. GM Eliopoulos K Klimm CT Eliopoulos 1993 In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria Antimicrob Agents Chemother 37 366 70 8452372 10.1128/AAC.37.2.366 1:CAS:528:DyaK3sXhs1GjtL0%3D Eliopoulos GM, Klimm K, Eliopoulos CT, et al. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother 1993; 37: 366–70
5. 5. PC Appelbaum 1995 Quinolone activity against anaerobes: microbiological aspects Drugs 2 76 80 10.2165/00003495-199500492-00012 Appelbaum PC. Quinolone activity against anaerobes: microbiological aspects. Drugs 1995; 49 Suppl. 2: 76–80
6. 6. GE Kenny FD Cartwright 1996 Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219) Antimicrob Agents Chemother 40 1048 9 8849228 1:CAS:528:DyaK28XitVWqt7o%3D Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrob Agents Chemother 1996; 40: 1048–9
7. 7. KP Klugman 1997 In-vitro and in vivo activity of trovafloxacin against Streptococcus pneumoniae J Antimicrob Chemother 39 51 5 9222070 10.1093/jac/39.suppl_2.51 1:CAS:528:DyaK2sXksFWqt7w%3D Klugman KP. In-vitro and in vivo activity of trovafloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1997; 39 Suppl. B: 51–5
8. 8. JM Andrews D Honeybourne NP Brenwald 1997 Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy J Antimicrob Chemother 39 797 802 9222050 10.1093/jac/39.6.797 1:CAS:528:DyaK2sXksFWqsb4%3D Andrews JM, Honeybourne D, Brenwald NP, et al. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1997; 39: 797–802
9. 9. J Vincent R Teng LC Dogolo 1996 Trovafloxacin and ofloxacin profiles in ambulatory subjects matched for age and gender [abstract no. A6]. Proceedings of 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, Louisiana American Society for Microbiology Washington DC 2 Vincent J, Teng R, Dogolo LC, et al. Trovafloxacin and ofloxacin profiles in ambulatory subjects matched for age and gender [abstract no. A6]. Proceedings of 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, Louisiana. Washington DC: American Society for Microbiology, 1996: 2